Hims & Hers Health ( (HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Hims & Hers Health, Inc. recently saw its stock rise by 4.5% following the announcement of closing its acne treatment business, Apostrophe, to focus on dermatology services. However, analysts remain cautious due to regulatory challenges in the weight-loss drug market, particularly with FDA decisions on semaglutide and tirzepatide shortages. These issues could affect the company’s ability to sell compounded GLP-1 drugs, crucial for their revenue goals. Additionally, competition from companies like Lilly and Novo Nordisk launching direct-to-consumer pharmacy platforms threatens Hims & Hers’ market share, prompting analysts to maintain conservative ratings.
More about Hims & Hers Health
YTD Price Performance: 37.74%
Average Trading Volume: 20,678,063
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $7.71B
For further insights into HIMS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.
Questions or Comments about the article? Write to editor@tipranks.com